1. Introduction & Classification

Femara (generic name: Letrozole) is a prescription medication classified as an Aromatase Inhibitor (AI), specifically a nonsteroidal, competitive inhibitor of the aromatase enzyme. It is widely used in oncology for the treatment and prevention of hormone receptor-positive breast cancer in postmenopausal women.

2. Mechanism of Action

Letrozole exerts its anticancer effect by selectively inhibiting the aromatase enzyme (CYP19A1), which catalyzes the conversion of androgens (androstenedione and testosterone) into estrogens (estradiol, estrone). This results in a significant reduction in circulating estrogen levels.

• Pharmacodynamic Effect:
  • Decreases serum estradiol, estrone, and estrone sulfate.
  • Does not affect adrenal steroidogenesis or mineralocorticoid synthesis.
  • Unlike surgical or medical ovariectomy, letrozole does not increase FSH levels due to its selective action on ovarian rather than pituitary function.
• Evidence Base:
  • In vitro and animal studies demonstrate potent suppression of estrogen-dependent tumor growth (1).
  • Clinical trials confirm efficacy in both early-stage (adjuvant) and advanced/metastatic breast cancer settings.

3. Indications

• First-line adjuvant therapy for hormone receptor-positive, HER2-negative, postmenopausal women with early breast cancer recurrence risk after 5 years of tamoxifen.
• Treatment of advanced/metastatic hormone receptor-positive breast cancer in postmenopausal women who have progressed on prior antiestrogen therapy.

4. Dosage & Administration

• Standard Adult Dose:
  • 2.5 mg orally once daily, with or without food.
  • Consistency is key; take at the same time each day.
• Adjuvant Use:
  • After completion of 5 years of adjuvant tamoxifen therapy.
• Special Populations:
  • Liver impairment: Dose adjustment may be required (e.g., alternate-day dosing in severe cirrhosis).
  • Renal impairment: No dose adjustment needed.

5. Pharmacokinetics

• Absorption: Good oral bioavailability (~80%).
• Metabolism: Primarily hepatic via CYP3A4.
• Excretion: Mainly fecal (unmetabolized drug).
• Half-life: Approximately 35–54 hours, supporting once-daily dosing.

6. Efficacy & Clinical Outcomes

• Reduction in recurrence risk and improvement in overall survival when used as adjuvant therapy (2).
• Metastatic disease: Significant prolongation of progression-free survival (PFS) compared to older endocrine therapies.

7. Adverse Effects & Monitoring

Common Side Effects:

• Musculoskeletal: Arthralgia, myalgia, back pain
• Gastrointestinal: Nausea, vomiting, diarrhea, constipation
• Neurological: Headache
• Other: Fatigue, chest discomfort

Laboratory Findings:

• Hypercholesterolemia: Increased LDL and total cholesterol; lipid profile monitoring recommended.
• Bone Health: Decreased bone mineral density (BMD) and increased risk of osteoporosis/fractures. Consider baseline and periodic DEXA scans, especially in high-risk patients (3).
• Hepatic Function: Monitor liver enzymes if pre-existing disease is present.

Other:

• Infertility (may affect both sexes)
• Rare reports of severe arthralgia, tendon rupture, and rarely, adrenal insufficiency (due to off-target effects on steroidogenesis).

8. Drug Interactions

• CYP3A4 modulators: Strong inducers/inhibitors may alter plasma levels.
• Other endocrine therapies: Concurrent use with tamoxifen or ovarian suppression agents requires careful monitoring for additive effects and toxicity.
• Statins, anticoagulants, antidiabetics: Potential pharmacokinetic interactions; monitor closely.

9. Contraindications & Precautions

• Absolute contraindications:
  • Pregnancy (risk of fetal harm; teratogenicity confirmed in animal models)
  • Lactation (potential for infant exposure)
  • Known hypersensitivity to letrozole or any excipient
• Relative contraindications:
  • Severe hepatic impairment, pre-existing osteoporosis, uncontrolled hypercholesterolemia

10. Drug Safety & Counseling Points

• Pregnancy Prevention: Effective contraception is mandatory during therapy and for at least 3 months post-discontinuation.
• Storage: Store at room temperature, away from moisture/light.
• Disposal: Follow local guidelines; do not flush or discard unused medication in household waste.

11. Special Populations

• Elderly: No dose adjustment needed unless comorbidities present.
• Renal/Liver Disease: Monitor closely; consider alternate dosing if severe impairment.
• Pediatric: Not indicated for premenopausal girls or children.

12. Summary for Pharmacists

Femara (letrozole) is a cornerstone in the management of hormone receptor-positive breast cancer, offering significant survival benefits and disease control. Pharmacists play a vital role in:

• Ensuring correct dosing and administration
• Monitoring for adverse effects (especially bone health and lipid changes)
• Advising on drug interactions and contraindications
• Supporting patient education regarding side effect management and the importance of adherence

References:

1. Sledge GW, et al. Letrozole in postmenopausal women with hormone receptor–positive breast cancer. N Engl J Med. 2001.
2. Early Breast Cancer Trialists’ Collaborative Group. Effect of aromatase inhibitors vs tamoxifen on recurrence and survival in early breast cancer. Lancet. 2007.
3. Sledge GW, et al. Bone mineral density changes with letrozole therapy in postmenopausal women. J Clin Oncol. 2012.

In summary: Femara is a potent, well-studied AI with robust evidence supporting its use in breast cancer management. Pharmacists should be vigilant for adverse effects, especially on bone and lipid metabolism, and ensure patients are counseled about contraception, monitoring, and safe medication practices.